Cargando…
Advances in immunotherapy modalities for atherosclerosis
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of f...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871313/ https://www.ncbi.nlm.nih.gov/pubmed/36703734 http://dx.doi.org/10.3389/fphar.2022.1079185 |
_version_ | 1784877142707798016 |
---|---|
author | Meng, Qingwen Liu, Huajiang Liu, Jinteng Pang, Yangyang Liu, Qibing |
author_facet | Meng, Qingwen Liu, Huajiang Liu, Jinteng Pang, Yangyang Liu, Qibing |
author_sort | Meng, Qingwen |
collection | PubMed |
description | Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of factors, including endothelial dysfunction, lipid deposits in the artery wall, and monocyte-derived macrophage infiltration, in which both innate immunity and adaptive immunity play an indispensable role. Recent studies have shown that atherosclerosis can be alleviated by inducing a protective immune response through certain auto-antigens or exogenous antigens. Some clinical trials have also demonstrated that atherosclerotic is associated with the presence of immune cells and immune factors in the body. Therefore, immunotherapy is expected to be a new preventive and curative measure for atherosclerosis. In this review, we provide a summary overview of recent progress in the research of immune mechanisms of atherosclerosis and targeted therapeutic pathways. |
format | Online Article Text |
id | pubmed-9871313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98713132023-01-25 Advances in immunotherapy modalities for atherosclerosis Meng, Qingwen Liu, Huajiang Liu, Jinteng Pang, Yangyang Liu, Qibing Front Pharmacol Pharmacology Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Atherosclerosis is the pathological basis of atherosclerotic cardiovascular disease (ASCVD). Atherosclerosis is now understood to be a long-term immune-mediated inflammatory condition brought on by a complicated chain of factors, including endothelial dysfunction, lipid deposits in the artery wall, and monocyte-derived macrophage infiltration, in which both innate immunity and adaptive immunity play an indispensable role. Recent studies have shown that atherosclerosis can be alleviated by inducing a protective immune response through certain auto-antigens or exogenous antigens. Some clinical trials have also demonstrated that atherosclerotic is associated with the presence of immune cells and immune factors in the body. Therefore, immunotherapy is expected to be a new preventive and curative measure for atherosclerosis. In this review, we provide a summary overview of recent progress in the research of immune mechanisms of atherosclerosis and targeted therapeutic pathways. Frontiers Media S.A. 2023-01-10 /pmc/articles/PMC9871313/ /pubmed/36703734 http://dx.doi.org/10.3389/fphar.2022.1079185 Text en Copyright © 2023 Meng, Liu, Liu, Pang and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Meng, Qingwen Liu, Huajiang Liu, Jinteng Pang, Yangyang Liu, Qibing Advances in immunotherapy modalities for atherosclerosis |
title | Advances in immunotherapy modalities for atherosclerosis |
title_full | Advances in immunotherapy modalities for atherosclerosis |
title_fullStr | Advances in immunotherapy modalities for atherosclerosis |
title_full_unstemmed | Advances in immunotherapy modalities for atherosclerosis |
title_short | Advances in immunotherapy modalities for atherosclerosis |
title_sort | advances in immunotherapy modalities for atherosclerosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871313/ https://www.ncbi.nlm.nih.gov/pubmed/36703734 http://dx.doi.org/10.3389/fphar.2022.1079185 |
work_keys_str_mv | AT mengqingwen advancesinimmunotherapymodalitiesforatherosclerosis AT liuhuajiang advancesinimmunotherapymodalitiesforatherosclerosis AT liujinteng advancesinimmunotherapymodalitiesforatherosclerosis AT pangyangyang advancesinimmunotherapymodalitiesforatherosclerosis AT liuqibing advancesinimmunotherapymodalitiesforatherosclerosis |